(Q39523026)

12 September 2017

1 reference

title

Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics (English)

1 reference

12 September 2017

1 reference

1 reference

Holthuis JJ

1

1 reference

12 September 2017

1 June 1988

1 reference

Pharmaceutisch weekblad. Scientific edition

12 September 2017

1 reference

12 September 2017

10

1 reference

12 September 2017

3

1 reference

12 September 2017

101-116

1 reference

Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells

12 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF01959294

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01959294

PTG, a new antineoplastic epipodophyllotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01959294

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01959294

Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

21 January 2018

1 reference

12 December 2020

EPEG, a new antineoplastic epipodophyllotoxin

1 reference

12 December 2020

Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors

1 reference

12 December 2020

High-dose etoposide for refractory malignancies: a phase I study

1 reference

12 December 2020

Pharmacokinetics of teniposide in patients with ovarian cancer

1 reference

12 December 2020

Pharmacokinetics of VP16-213 given by different administration methods

1 reference

12 December 2020

High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma

1 reference

12 December 2020

Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography

1 reference

12 December 2020

Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide

1 reference

12 December 2020

High-performance liquid chromatography of etoposide in plasma and urine

1 reference

12 December 2020

Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action

1 reference

12 December 2020

The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26

1 reference

12 December 2020

Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

1 reference

12 December 2020

Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver.

1 reference

12 December 2020

Etoposide: a pharmacokinetic profile including an assessment of bioavailability

1 reference

12 December 2020

Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.

1 reference

12 December 2020

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

1 reference

12 December 2020

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide

1 reference

12 December 2020

Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography

1 reference

12 December 2020

Teniposide (VM26) disposition in children with leukemia.

1 reference

12 December 2020

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients

1 reference

12 December 2020

Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

Review of etoposide single-agent activity

1 reference

12 December 2020

Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents

1 reference

12 December 2020

Pharmacokinetics of etoposide in gestochoriocarcinoma

1 reference

12 December 2020

[Partial synthesis of 4'-demethylepipodophyllotoxin]

1 reference

12 December 2020

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function

1 reference

12 December 2020

Phase I trial of a new form of an oral administration of VP-16-213

1 reference

12 December 2020

Inactivation of phi X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213

1 reference

12 December 2020

High-performance liquid chromatographic assay for etoposide in human plasma

1 reference

12 December 2020

Radioimmunoassay for etoposide and teniposide.

1 reference

12 December 2020

VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide.

1 reference

12 December 2020

Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.

1 reference

12 December 2020

High-performance liquid chromatographic method for the determination of etoposide in plasma using electrochemical detection

1 reference

12 December 2020

Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1 reference

12 December 2020

Etoposide (VP-16-213). Current status of an active anticancer drug

1 reference

12 December 2020

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer

1 reference

12 December 2020

Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1 reference

12 December 2020

Stability-indicating liquid chromatographic determination of etoposide and benzyl alcohol in injectable formulations.

1 reference

12 December 2020

Automated liquid chromatographic analysis of the anti-tumorigenic drugs etoposide (VP 16-213) and teniposide (VM 26)

1 reference

12 December 2020

High-dose teniposide for refractory malignancies: a phase I study

1 reference

12 December 2020

Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.

1 reference

12 December 2020

Bioavailability and pharmacokinetics of etoposide (VP-16)

1 reference

12 December 2020

On a new glycoside synthesis process. II. Glycosides of 4'-demethylepipodophyllotoxins

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection

1 reference

12 December 2020

Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite.

1 reference

12 December 2020

Determination of etoposide (VP16-213) and teniposide (VM-26) in serum by high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins

1 reference

12 December 2020

Measurement of plasma etoposide by radio-immunoassay.

1 reference

12 December 2020

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration

1 reference

12 December 2020

Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolit

1 reference

12 December 2020

Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship

1 reference

12 December 2020

Stability-indicating high-performance liquid chromatography of etoposide at various pH conditions using a reversed-phase octyl column

1 reference

12 December 2020

A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide

1 reference

12 December 2020

Free radical formation from the antineoplastic agent VP 16-213

1 reference

12 December 2020

In vitro and in vivo metabolism of VP 16-213 in the rat

1 reference

12 December 2020

Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

1 reference

12 December 2020

PHASE I clinical trial of an oral solution of VP-16-213

1 reference

12 December 2020

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

12 December 2020

Irreversible binding of etoposide (VP-16-213) to deoxyribonucleic acid and proteins

1 reference

12 December 2020

Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26)

1 reference

12 December 2020

The biological effects and the chemical composition of podophyllin: a review

1 reference

12 December 2020

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease

1 reference

12 December 2020

Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry

1 reference

12 December 2020

The clinical pharmacology of VM26 and VP16-213. A brief overview

1 reference

12 December 2020

Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage

1 reference

12 December 2020

Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro

1 reference

12 December 2020

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

1 reference

12 December 2020

A radioimmunoassay for VP16-213 in plasma

1 reference

12 December 2020

Pharmacokinetics of high dose etoposide (VP 16-213)

1 reference

12 December 2020

Clinical pharmacology of intracarotid etoposide.

1 reference

12 December 2020

Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage

1 reference

12 December 2020

Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners

1 reference

12 December 2020

Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans

1 reference

12 December 2020

High-performance liquid chromatographic determination of etoposide in plasma using electrochemical detection

1 reference

12 December 2020

Pharmacokinetics of high-dose teniposide.

1 reference

12 December 2020

Teniposide: a review of 12 years of experience.

1 reference

12 December 2020

The role of metabolic activation by cytochrome P-450 in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01959294

1 reference

12 September 2017

1 reference

PubMed ID

3047665